Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market Research Report: (2022-2027)

Market Definition

CAR T-cell therapy is a type of immunotherapy that uses altered immune cells (T-cells) to find & attack tumor cells. During the therapy, a patient’s T cells are extracted & genetically altered to express a CAR (Chimeric Antigen Receptor) that recognizes a protein on the surface of cancer cells. The modified T-cells are then multiplied & infused back into the patient, where they identify & destroy tumor cells and might remain in the body for months after the infusion.

The therapy can result in severe side effects, which is why patients stay in the hospital for a week or two for monitoring. Its efficacy in the treatment of hematologic malignancies has been well-proved, and there are numerous ongoing research activities to identify if it helps treat solid tumors.

Market Insights

The Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market is projected to register exponential CAGR during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the burgeoning adoption of CAR T-cell therapy to address the rising patient pool for blood cancers, including lymphomas, certain forms of leukemia, & also multiple myeloma, on account of the mounting awareness regarding its benefits over traditional treatments.

Various ongoing R&D activities in the life science & biotechnology sectors across numerous countries for blood cancer treatment using chimeric antigen receptors to evaluate CAR T-cell therapy's effectiveness, safety, mechanism of drug action, and adherence in patients with lymphoma & leukemia are also augmenting the overall growth of the global market.

The approvals of Kymriah & Yescarta earlier in 2017, their expansion across Japan & Europe during 2018-19, and their steadily growing global sales have proved to be a milestone for the Global CAR T-cell Therapy Market. Since then, there have been rapid & notable developments in the field as researchers are tweaking the efficacy & safety of CAR T-cells using novel approaches.

Despite the immense success of CAR T-cell therapy in treating blood cancers, there's still a major missing to its full potential since its application is limited only to certain liquid tumors in relapsed & refractory stages. Challenges like complex manufacturing & supply chain, high costs, and delayed preapproval reimbursement for patients are affecting its commercialization and, in turn, hampering the market growth.

However, with the optimization of autologous CAR T-cells for liquid malignancies, expansion of healthcare facilities, and fast & innovative developments of effective biomarkers to treat solid tumors, the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market could witness remunerative prospects over the coming years.

Market Segmentation

Based on Drug Class:

• By Drug Class
  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Others (Abecma (Idecabtagene vicleucel), etc.)

Amongst all drugs, Yescarta holds the largest share in the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, and the same trend is likely to be followed during 2022-27. It was the first FDA-approved drug for the treatment of adults with relapsed or refractory large B-cell lymphoma if the first-line systematic therapy, i.e., chemotherapy, fails.

Although Kymriah (tisagenlecleucel), the first gene therapy approved by the FDA in 2017 for patients (up to 25 years of age) with B-cell precursor ALL (Acute Lymphoblastic Leukemia), either refractory, in second, or later relapse, displayed promising survival rates in clinical trials.

However, due to some manufacturing issues, dissatisfactory outcomes in the standard treatment in a late-stage study of patients with relapsed or refractory lymphoma, & higher prices, Kymriah's overall sales & demand are lagging behind Yescarta.

Moreover, compared to the SOC (Standard-of-Care), i.e., chemotherapy & stem cell transplant, axicabtagene ciloleucel has significantly reduced the risk of disease progression, death, or the need for a new treatment. Hence, based on these aspects, Yescarta would continue dominating the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market through 2027.

Based on Application:

• Acute Lymphocytic Leukemia (ALL)
• Diffuse Large B-cell Lymphoma (DLBCL)
• Follicular Lymphoma
• Multiple Myeloma
• Others (Mantle Cell Lymphoma, etc.)

Here, Diffuse Large B-cell Lymphoma (DLBCL), followed by Acute Lymphocytic Leukemia (ALL), dominates the market with the largest share. It attributes to the mounting prevalence of NHL (Non-Hodgkin Lymphoma), coupled with rapidly increasing approvals for therapeutics for patients with relapsed or refractory diffuse large b-cell lymphoma.

DLBCL, an aggressive NHL that affects the B-lymphocytes, can grow in either lymph nodes or areas outside them. The leading biopharma companies are focusing actively on attaining approvals from regulatory authorities for relapsed or refractory therapeutics for the same.

• In February 2021, the US FDA approved Breyanzi (lisocabtagene maraleucel), a CAR T-cell therapy, as a treatment for DLBCL adult patients who have not responded to or relapsed after at least two lines of SOC.

On the other hand, multiple myeloma can be the next promising opportunity for the global market in the coming years. Since myeloma is currently incurable, using CAR T-cells in its early stages might lead to better remission and, in turn, a cure.

• In March 2021, the US FDA approved Abecma (idecabtagene vicleucel), i.e., a B-Cell Maturation Antigen (BCMA)-directed genetically modified autologous therapy, to treat adults with refractory or relapsed multiple myeloma after at least four lines of systematic treatment.
• In February 2022, another BCMA-directed genetically modified autologous therapy, CARVYKTI (ciltacabtagene autoleucel), was approved by FDA for the treatment of adult patients with relapsed or refractory multiple myeloma after at least four prior lines of SOC, including an anti-CD38 monoclonal antibody, immunomodulatory agent, and a proteasome inhibitor.

Regional Landscape

Geographically, the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market expands across:

• North America
• South America
• Europe
• Middle East & Africa
• Asia-Pacific

Among all regions, North America accounts for the largest share in the Global CAR T-Cell Therapy Market, and the same trend is likely over the forecast years. The regional market is driven primarily by the extensive presence of leading biotechnology & pharmaceutical firms, early adoption of new healthcare technologies, rapid approvals for novel therapies, and the rising incidence of leukemia & lymphoma & massive investments in developing more effective therapeutics.

During 2022-27, the US will be leading the North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market owing to the increasing number of life sciences firms actively focusing on enhancing quality control systems as well as developing CAR T-cells & making them commercially available across the country. Moreover, the well-established healthcare facilities, research centers & labs across the country are also driving the CAR T-Cell Therapy Market in the US.

Key Questions Answered in the Market Research Report:

1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market?
2. What are the region-wise industry size, growth drivers, and challenges?
3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market?
4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market based on the competitive benchmarking matrix?
5. What are the key results derived from surveys conducted during the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market study?